Angiotensin analogs: the influence of sarcosine substituted in position 1.
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004357:Drug Synergism; D010450:Endopeptidases / Q000097:blood; D005260:Female; D006207:Half-Life; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D007532:Isoleucine / Q000494:pharmacology; D007668:Kidney / Q000201:enzymology; D007931:Leucyl Aminopeptidase / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D011480:Protease Inhibitors; D011485:Protein Binding; D011817:Rabbits; D011955:Receptors, Drug / Q000187:drug effects; D012521:Sarcosine / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D011480:Protease Inhibitors; D011955:Receptors, Drug; D007532:Isoleucine; D000804:Angiotensin II; D010450:Endopeptidases; D007931:Leucyl Aminopeptidase; D012521:Sarcosine